Objective: To analyze the effectiveness and adverse reactions of using halometasone cream combined with tacrolimus ointment in the treatment of facial seborrheic dermatitis. Methods:A cohort of 80 patients diagnosed with seborrheic dermatitis affecting the head and face was enrolled at our institution between January 2025 and January 2026. Utilizing a random number table, subjects were allocated equally into two groups (n=40 each). The control arm received monotherapy with tacrolimus ointment, whereas the observation arm was administered a combination regimen of halometasone and tacrolimus ointments. Subsequent analyses compared the two cohorts regarding overall efficacy, dermatological symptom scores, recurrence rates, and the incidence of adverse reactions. Results: Statistical analysis revealed that the observation group achieved a significantly superior total effective rate compared to the control group (P < 0.05). Furthermore, post-treatment evaluations indicated that scores for specific skin manifestations—including pityriasis-like scaling, erythema, and stinging sensations—were markedly reduced in the observation cohort relative to the control cohort (P < 0.05). Regarding long-term prognosis, the observation group exhibited a lower disease recurrence frequency (P < 0.05). Notably, the incidence of treatment-related adverse events did not differ significantly between the two groups (P > 0.05)Conclusion: Therapeutic intervention utilizing a combination of halometasone cream and tacrolimus ointment has been shown to significantly elevate the overall clinical efficacy in patients with facial seborrheic dermatitis, effectively alleviate skin symptoms such as dandruff-like desquamation, redness, and stinging, reduce the recurrence rate of the disease, and does not increase the risk of adverse reactions, showing good efficacy and safety.